IQVIA Holdings Inc. logo
IQVIA Holdings Inc. (IQV)
Compare

IQVIA Holdings Inc. (IQV) EV/Assets Ratio: 1.51x

Is IQVIA Holdings Inc.’s EV/Assets ratio high or low?

IQVIA Holdings Inc.'s EV/Assets ratio of 1.51x is 24% below its 5-year average of 1.99x, near the low end of its 5-year range (1.36x–2.76x).

As of Sunday, June 14, 2026. 6.39% below its 12-month average of 1.61x.

IQV EV/Assets Ratio Chart

IQV EV/Assets Ratio
1.51x+0.67% 1Y
Zoom

IQV Average EV/Assets Ratio Chart

IQV Current vs Average EV/Assets Ratio Chart

IQV EV/Assets Ratio Metrics

EV/ASSETS RATIO

1.51x

EV/ASSETS RATIO AVG TTM

1.61x

EV/ASSETS RATIO AVG 3Y

1.83x

EV/ASSETS RATIO AVG 5Y

1.99x

EV/ASSETS RATIO AVG 10Y

1.87x

EV/ASSETS RATIO AVG 15Y

N/A

EV/ASSETS RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

-6.39%

CURRENT VS 3Y AVG

-17.41%

CURRENT VS 5Y AVG

-24.21%

CURRENT VS 10Y AVG

-19.43%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

IQV Competitors' EV/Assets Ratio

NAMEMARKET CAPEV/ASSETS RATIOTTM3Y5Y
IQVIA Holdings Inc. (IQV)$30.29B1.51x1.61x1.83x1.99x
Medline Inc. (MDLN)vs ›$30.96B1.04x1.17x1.17x1.17x
Biogen Inc. (BIIB)vs ›$29.53B1.11x0.96x1.19x1.43x
DexCom, Inc. (DXCM)vs ›$29.08B4.51x4.22x5.88x7.46x
Centene Corporation (CNC)vs ›$32.19B0.34x0.25x0.39x0.51x
Zoetis Inc. (ZTS)vs ›$33.36B2.70x4.24x5.43x5.83x
Veeva Systems Inc. (VEEV)vs ›$25.92B2.70x4.61x5.32x6.97x
Agilent Technologies, Inc. (A)vs ›$36.67B2.94x3.06x3.38x3.71x
Waters Corporation (WAT)vs ›$23.17B1.40x4.10x4.54x5.46x
United Therapeutics Corporation (UTHR)vs ›$23.17B3.68x2.69x2.17x2.06x

IQVIA Holdings Inc. EV/Assets Ratio Formula & Definition

EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

IQVIA Holdings Inc. EV/Assets Ratio FAQ

What is the EV/Assets ratio for IQVIA Holdings Inc. (IQV)?
The EV/Assets ratio for IQV stock is 1.51x.
Is IQVIA Holdings Inc.'s EV/Assets ratio high or low?
IQVIA Holdings Inc.'s EV/Assets ratio of 1.51x is 24% below its 5-year average of 1.99x, near the low end of its 5-year range (1.36x–2.76x).
What is the TTM average EV/Assets ratio for IQVIA Holdings Inc. (IQV)?
The TTM average EV/Assets ratio for IQV stock is 1.61x.
What is the 3Y average EV/Assets ratio for IQVIA Holdings Inc. (IQV)?
The 3Y average EV/Assets ratio for IQV stock is 1.83x.
What is the 5Y average EV/Assets ratio for IQVIA Holdings Inc. (IQV)?
The 5Y average EV/Assets ratio for IQV stock is 1.99x.
What is the 10Y average EV/Assets ratio for IQVIA Holdings Inc. (IQV)?
The 10Y average EV/Assets ratio for IQV stock is 1.87x.

IQVIA Holdings Inc. EV/Assets Ratio History

DATEEV/ASSETS RATIO
2026-06-121.51x
2026-06-111.51x
2026-06-101.52x
2026-06-091.54x
2026-06-081.53x
2026-06-051.53x
2026-06-041.55x
2026-06-031.52x
2026-06-021.51x
2026-06-011.54x
2026-05-291.52x
2026-05-281.51x
2026-05-271.42x
2026-05-261.40x
2026-05-221.44x
2026-05-211.44x
2026-05-201.46x
2026-05-191.47x
2026-05-181.46x
2026-05-151.44x
2026-05-141.45x
2026-05-131.46x
2026-05-121.48x
2026-05-111.47x
2026-05-081.50x
2026-05-071.50x
2026-05-061.49x
2026-05-051.49x
2026-05-041.40x
2026-05-011.38x
2026-04-301.38x
2026-04-291.37x
2026-04-281.39x
2026-04-271.41x
2026-04-241.41x
2026-04-231.40x
2026-04-221.48x
2026-04-211.48x
2026-04-201.49x
2026-04-171.49x
2026-04-161.46x
2026-04-151.50x
2026-04-141.48x
2026-04-131.46x
2026-04-101.43x
2026-04-091.44x
2026-04-081.46x
2026-04-071.45x
2026-04-061.45x
2026-04-021.47x
2026-04-011.46x
2026-03-311.45x
2026-03-301.43x
2026-03-271.41x
2026-03-261.45x
2026-03-251.42x
2026-03-241.43x
2026-03-231.43x
2026-03-201.43x
2026-03-191.43x
2026-03-181.43x
2026-03-171.44x
2026-03-161.42x
2026-03-131.42x
2026-03-121.41x
2026-03-111.46x
2026-03-101.46x
2026-03-091.50x
2026-03-061.48x
2026-03-051.50x
2026-03-041.50x
2026-03-031.47x
2026-03-021.47x
2026-02-271.50x
2026-02-261.45x
2026-02-251.40x
2026-02-241.42x
2026-02-231.41x
2026-02-201.42x
2026-02-191.45x
2026-02-181.46x
2026-02-171.42x
2026-02-131.46x
2026-02-121.47x
2026-02-111.52x
2026-02-101.56x
2026-02-091.62x
2026-02-061.59x
2026-02-051.55x
2026-02-041.68x
2026-02-031.68x
2026-02-021.85x
2026-01-301.84x
2026-01-291.87x
2026-01-281.90x
2026-01-271.91x
2026-01-261.90x
2026-01-231.87x
2026-01-221.89x
2026-01-211.91x
2026-01-201.86x
2026-01-161.89x
2026-01-151.91x
2026-01-141.91x
2026-01-131.91x
2026-01-121.91x
2026-01-091.91x
2026-01-081.92x
2026-01-071.93x
2026-01-061.90x
2026-01-051.87x
2026-01-021.81x
2025-12-311.81x
2025-12-301.83x
2025-12-291.82x
2025-12-261.82x
2025-12-241.82x
2025-12-231.81x
2025-12-221.81x
2025-12-191.78x
2025-12-181.80x
2025-12-171.79x
2025-12-161.79x
2025-12-151.80x
2025-12-121.79x
2025-12-111.82x
2025-12-101.80x
2025-12-091.77x
2025-12-081.80x
2025-12-051.82x
2025-12-041.81x
2025-12-031.82x
2025-12-021.81x
2025-12-011.83x
2025-11-281.84x
2025-11-261.85x
2025-11-251.85x
2025-11-241.83x
2025-11-211.81x
2025-11-201.76x
2025-11-191.77x
2025-11-181.76x
2025-11-171.76x
2025-11-141.78x
2025-11-131.80x
2025-11-121.79x
2025-11-111.77x
2025-11-101.74x
2025-11-071.72x
2025-11-061.73x
2025-11-051.72x
2025-11-041.73x
2025-11-031.74x
2025-10-311.76x
2025-10-301.76x
2025-10-291.77x
2025-10-281.77x
2025-10-271.79x
2025-10-241.81x
2025-10-231.81x
2025-10-221.79x
2025-10-211.80x
2025-10-201.76x
2025-10-171.71x
2025-10-161.72x
2025-10-151.71x
2025-10-141.72x
2025-10-131.71x
2025-10-101.68x
2025-10-091.71x
2025-10-081.69x
2025-10-071.69x
2025-10-061.72x
2025-10-031.73x
2025-10-021.71x
2025-10-011.71x
2025-09-301.63x
2025-09-291.57x
2025-09-261.56x
2025-09-251.55x
2025-09-241.57x
2025-09-231.60x
2025-09-221.61x
2025-09-191.61x
2025-09-181.63x
2025-09-171.61x
2025-09-161.61x
2025-09-151.60x
2025-09-121.61x
2025-09-111.63x
2025-09-101.59x
2025-09-091.62x
2025-09-081.61x
2025-09-051.61x
2025-09-041.59x
2025-09-031.59x
2025-09-021.59x
2025-08-291.63x
2025-08-281.62x
2025-08-271.62x
2025-08-261.61x
2025-08-251.61x
2025-08-221.63x
2025-08-211.60x
2025-08-201.64x
2025-08-191.64x
2025-08-181.64x
2025-08-151.63x
2025-08-141.62x
2025-08-131.63x
2025-08-121.60x
2025-08-111.57x
2025-08-081.57x
2025-08-071.56x
2025-08-061.55x
2025-08-051.59x
2025-08-041.58x
2025-08-011.58x
2025-07-311.60x
2025-07-301.64x
2025-07-291.65x
2025-07-281.67x
2025-07-251.68x
2025-07-241.69x
2025-07-231.65x
2025-07-221.61x
2025-07-211.50x
2025-07-181.51x
2025-07-171.53x
2025-07-161.50x
2025-07-151.49x
2025-07-141.51x
2025-07-111.52x
2025-07-101.54x
2025-07-091.52x
2025-07-081.54x
2025-07-071.52x
2025-07-031.53x
2025-07-021.54x
2025-07-011.52x
2025-06-301.49x
2025-06-271.49x
2025-06-261.49x
2025-06-251.50x
2025-06-241.50x
2025-06-231.47x
2025-06-201.47x
2025-06-181.47x
2025-06-171.47x
2025-06-161.50x
2025-06-131.49x
2025-06-121.50x
2025-06-111.50x
2025-06-101.50x
2025-06-091.47x
2025-06-061.46x
2025-06-051.42x
2025-06-041.43x
2025-06-031.39x
2025-06-021.37x

Showing the most recent 260 of 3,172 data points. The chart above shows the full history.

About IQVIA Holdings Inc.

IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.

Durham, NC
89,000 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Ari Bousbib